Ligand Pharmaceuticals - Biopharma's Technology and Capital …
Ligand invests in the clinical development and commercialization of high-value medicines. We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 100 partnered commercial and development stage programs.
Ligand Pharmaceuticals Incorporated - Investor Relations
2024年11月7日 · Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of high-value programs that can improve and extend lives around the world.
Royalty Portfolio - Ligand Pharmaceuticals
Today, Ligand manages one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 100 partnered commercial and development stage programs. The assets in our portfolio include treatments for cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and other rare conditions that threaten ...
Team - Ligand Pharmaceuticals
Before joining Ligand, Dr. Reeves served as President and Chief Medical Officer of AZTherapies, Inc., a private, late-stage clinical biopharmaceutical company focused on developing drugs for neuroinflammation and severe neurological conditions, including Alzheimer’s and ALS.
Ligand Reports Third Quarter 2024 Financial Results and Raises …
Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.
Ligand Acquires CyDex Pharmaceuticals
2011年1月26日 · "This transformational acquisition accelerates Ligand's financial growth and provides a unique and broad basket of new assets to further expand our business and long-term potential," said John Higgins, President and Chief Executive Officer of Ligand.
Ligand Pharmaceuticals Incorporated - Financials - SEC Filings
2024年11月12日 · At Ligand Pharmaceuticals Incorporated, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further ...
Ligand Pharmaceuticals Incorporated - Ligand’s Partner Viking ...
2023年5月16日 · SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX) today announced positive top-line results from its Phase 2b clinical trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed ...
News & Events - Press Releases - Ligand Pharmaceuticals
2024年7月8日 · At Ligand Pharmaceuticals Incorporated, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further ...
Licensing - Ligand Pharmaceuticals
Roughly 40% of small molecule drug candidates have low solubility, which is why the world’s top pharmaceutical companies partner with Ligand and use Captisol as an important tool in the drug development process.
- 某些结果已被删除